So-called gonadotropin-releasing hormone agonists (GnRHa) are used to “immobilize” the ovaries during chemotherapy, which is hoped to protect the ovaries. At present, however, it is unclear by which mechanism this effect could be achieved.
Based on current studies, it is believed that the administration of GnRHa (e.g., as a monthly injection) beginning shortly before and continued during chemotherapy reduces the risk of premature ovarian function loss.
However, further studies are needed to determine whether this effect is real and whether a possible positive effect on ovarian function can be demonstrated in the long term.
Due to these uncertainties, if desired and possible, the administration of a GnRHa should not be performed alone but should be combined with another fertility preserving measures.